These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37540907)

  • 1. Barriers and facilitators to deprescribing before surgery: A qualitative study of providers and older adults.
    Lee JW; Jeong S; Han HR; Boyd CM; Perrin N; Simmons SF; Green AR; Taylor JL; Boucher HR; Szanton SL
    Geriatr Nurs; 2023; 53():135-140. PubMed ID: 37540907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers and facilitators of successful deprescribing as described by older patients living with frailty, their informal carers and clinicians: a qualitative interview study.
    Peat G; Fylan B; Marques I; Raynor DK; Breen L; Olaniyan J; Alldred DP
    BMJ Open; 2022 Mar; 12(3):e054279. PubMed ID: 35351709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barriers and enablers for deprescribing among older, multimorbid patients with polypharmacy: an explorative study from Switzerland.
    Zechmann S; Trueb C; Valeri F; Streit S; Senn O; Neuner-Jehle S
    BMC Fam Pract; 2019 May; 20(1):64. PubMed ID: 31088397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barriers, facilitators and needs to deprescribe benzodiazepines and other sedatives in older adults: a mixed methods study of primary care provider perspectives.
    Hürlimann O; Alers D; Hauri N; Leist P; Schneider C; Bolt L; Rodondi N; Aubert CE
    BMC Geriatr; 2024 May; 24(1):396. PubMed ID: 38704540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors influencing central nervous system medication deprescribing and behavior change in hospitalized older adults.
    Pavon JM; Zhang AD; Fish LJ; Falkovic M; Colón-Emeric CS; Gallagher DM; Schmader KE; Hastings SN
    J Am Geriatr Soc; 2024 Aug; 72(8):2359-2371. PubMed ID: 38826146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barriers and enablers for deprescribing benzodiazepine receptor agonists in older adults: a systematic review of qualitative and quantitative studies using the theoretical domains framework.
    Evrard P; Pétein C; Beuscart JB; Spinewine A
    Implement Sci; 2022 Jul; 17(1):41. PubMed ID: 35804428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What do older adults with multimorbidity and polypharmacy think about deprescribing? The LESS study - a primary care-based survey.
    Rozsnyai Z; Jungo KT; Reeve E; Poortvliet RKE; Rodondi N; Gussekloo J; Streit S
    BMC Geriatr; 2020 Oct; 20(1):435. PubMed ID: 33129274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors which influence the deprescribing decisions of community-living older adults and GPs in Australia.
    Gillespie R; Mullan J; Harrison L
    Health Soc Care Community; 2022 Nov; 30(6):e6206-e6216. PubMed ID: 36165345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. eConsultation for Deprescribing Among Older Adults: Clinician Perspectives on Implementation Barriers and Facilitators.
    Growdon ME; Hunt LJ; Miller MJ; Halim M; Karliner LS; Gonzales R; Sudore RL; Steinman MA; Harrison KL
    J Gen Intern Med; 2024 Oct; 39(13):2461-2470. PubMed ID: 38941059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Older Patient and Caregiver Perspectives on Medication Value and Deprescribing: A Qualitative Study.
    Pickering AN; Hamm ME; Dawdani A; Hanlon JT; Thorpe CT; Gellad WF; Radomski TR
    J Am Geriatr Soc; 2020 Apr; 68(4):746-753. PubMed ID: 32067226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis.
    Reeve J; Maden M; Hill R; Turk A; Mahtani K; Wong G; Lasserson D; Krska J; Mangin D; Byng R; Wallace E; Ranson E
    Health Technol Assess; 2022 Jul; 26(32):1-148. PubMed ID: 35894932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The patient's perspectives of safe and routine proactive deprescribing in primary care for older people living with polypharmacy: a qualitative study.
    Okeowo DA; Fylan B; Zaidi STR; Alldred DP
    BMC Geriatr; 2024 Oct; 24(1):844. PubMed ID: 39415136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges and opportunities in creating a deprescribing program in the emergency department: A qualitative study.
    Lee S; Bobb Swanson M; Fillman A; Carnahan RM; Seaman AT; Reisinger HS
    J Am Geriatr Soc; 2023 Jan; 71(1):62-76. PubMed ID: 36258309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deprescribing as an Opportunity to Facilitate Patient-Centered Care: A Qualitative Study of General Practitioners and Pharmacists in Japan.
    Ie K; Machino R; Albert SM; Tomita S; Kushibuchi M; Hirose M; Matsuda T; Okuse C; Ohira Y
    Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36834238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decision-Making Preferences and Deprescribing: Perspectives of Older Adults and Companions About Their Medicines.
    Weir K; Nickel B; Naganathan V; Bonner C; McCaffery K; Carter SM; McLachlan A; Jansen J
    J Gerontol B Psychol Sci Soc Sci; 2018 Sep; 73(7):e98-e107. PubMed ID: 29190369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploration of home care nurse's experiences in deprescribing of medications: a qualitative descriptive study.
    Sun W; Tahsin F; Barakat-Haddad C; Turner JP; Haughian CR; Abbass-Dick J
    BMJ Open; 2019 May; 9(5):e025606. PubMed ID: 31129579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers and enablers of older adults initiating a deprescribing conversation.
    Ailabouni NJ; Rebecca Weir K; Reeve E; Turner JT; Wilson Norton J; Gray SL
    Patient Educ Couns; 2022 Mar; 105(3):615-624. PubMed ID: 34183219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying barriers and facilitators to deprescribing benzodiazepines and sedative hypnotics in the hospital setting using the Theoretical Domains Framework and the Capability, Opportunity, Motivation and Behaviour (COM-B) Model: a qualitative study.
    Keller MS; Carrascoza-Bolanos J; Breda K; Kim LY; Kennelty KA; Leang DW; Murry LT; Nuckols TK; Schnipper JL; Pevnick JM
    BMJ Open; 2023 Feb; 13(2):e066234. PubMed ID: 36813499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a multicomponent communication training to involve older people in decisions to DEPRESCRIBE cardiometabolic medication in primary care (CO-DEPRESCRIBE): protocol for a cluster randomized controlled trial with embedded process and economic evaluation.
    Stuijt PJC; Heringa M; van Dijk L; Faber A; Burgers JS; Feenstra TL; Taxis K; Denig P
    BMC Prim Care; 2024 Jun; 25(1):210. PubMed ID: 38862899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-Reported Barriers and Enablers to Deprescribing Recommendations During a Clinical Trial (Shed-MEDS).
    Kim JL; Lewallen KM; Hollingsworth EK; Shah AS; Simmons SF; Vasilevskis EE
    Gerontologist; 2023 Mar; 63(3):523-533. PubMed ID: 35881109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.